NADPH oxidase 4 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13NADPH oxidase 4 shows clinical signal disease relevance led by head and neck squamous cell carcinoma. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9NPH5. Start with head and neck squamous cell carcinoma, then reuse UniProt Q9NPH5 as the stable protein anchor across project notes and exports.
Start with head and neck squamous cell carcinoma, then reuse UniProt Q9NPH5 as the stable protein anchor across project notes and exports.
NADPH oxidase 4 shows clinical signal disease relevance led by head and neck squamous cell carcinoma. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with head and neck squamous cell carcinoma because it currently carries clinical signal support. Linked drugs include SETANAXIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyNADPH oxidase 4
Review this target as NADPH oxidase 4, mapped to UniProt Q9NPH5. Sequence length is 578 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats NADPH oxidase 4 as ChEMBL target CHEMBL1250375, mapped to UniProt Q9NPH5. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether NADPH oxidase 4 is the right protein anchor across sources, using UniProt Q9NPH5 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why head and neck squamous cell carcinoma is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | NADPH oxidase 4 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q9NPH5 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | NADPH oxidase 4 |
| UniProt Accession | Q9NPH5 |
| Component Type | Protein |
| Sequence Length | 578 aa |
NADPH oxidase 4
Review this target as NADPH oxidase 4, mapped to UniProt Q9NPH5. Sequence length is 578 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
NADPH oxidase 4 shows clinical signal disease relevance led by head and neck squamous cell carcinoma. 3 more disease programs remain visible in the same review block.
Start review with head and neck squamous cell carcinoma because it currently carries clinical signal support. Linked drugs include SETANAXIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4859206 | 7.97 | IC50 | 10.71 | Preclinical |
| CHEMBL1876217 | 7.79 | IC50 | 16.4 | Preclinical |
| CHEMBL4849098 | 7.66 | IC50 | 21.94 | Preclinical |
| CHEMBL1277852 | 7.33 | Ki | 47.0 | Preclinical |
| CHEMBL1277767 | 7.19 | Ki | 65.0 | Preclinical |
| CHEMBL1927157 | 7.17 | Ki | 67.0 | Preclinical |
| CHEMBL388978 | 7.15 | IC50 | 70.77 | Preclinical |
| CHEMBL1927147 | 7.14 | Ki | 72.0 | Preclinical |
| CHEMBL1927149 | 7.12 | Ki | 76.0 | Preclinical |
| CHEMBL1277933 | 7.09 | Ki | 82.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 15 | 88 | 6.3 |
| single protein format | 7 | 34 | 6.1 |
| assay format | 3 | 24 | 5.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 17 | 7.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 3 | 5.2 |